Click Here for 5% Off Your First Aladdin Purchase!

lazucirnon , CAS No.1251528-23-0, Antagonist of CCR3

  • Moligand™
Item Number
L611461
Grouped product items
SKUSizeAvailabilityPrice Qty
L611461-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$550.90
L611461-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,900.90
View related series
CCR3 Antagonist

Basic Description

SynonymsLazucirnon|ALK4290|ALK-4290|AKST4290|1251528-23-0|Lazucirnon [USAN]|ALK429|AKST-4290|R0T9LLR4TN|BI144807|ALK-429|Lazucirnon (USAN)|2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionAntagonist of CCR3

Associated Targets

CCR3 Tchem C-C chemokine receptor type 3 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-carboxamide
INCHI InChI=1S/C27H34ClN5O3/c1-17-13-19(5-6-22(17)28)16-32-11-9-21(10-12-32)33-23(7-8-25(33)34)26(35)30-24-15-20(14-18(2)29-24)27(36)31(3)4/h5-6,13-15,21,23H,7-12,16H2,1-4H3,(H,29,30,35)/t23-/m1/s1
InChi Key DWKNOLCXIFYNFV-HSZRJFAPSA-N
Canonical SMILES O=C([C@H]1CCC(=O)N1C1CCN(CC1)Cc1ccc(c(c1)C)Cl)Nc1nc(C)cc(c1)C(=O)N(C)C
Isomeric SMILES CC1=CC(=CC(=N1)NC(=O)[C@H]2CCC(=O)N2C3CCN(CC3)CC4=CC(=C(C=C4)Cl)C)C(=O)N(C)C
PubChem CID 59534386

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Hirahara S, Nozaki M, Ohbayashi M, Hasegawa N, Ozone D, Ogura Y.  (2017)  Suppression of Retinal Neovascularization by Anti-CCR3 Treatment in an Oxygen-Induced Retinopathy Model in Mice..  Ophthalmic Res,  58  (1): (56-66).  [PMID:28376500]
2. Zhu C, Xu B, Sun X, Zhu Q, Sui Y.  (2017)  Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease..  Mol Neurobiol,  54  (10): (7964-7978).  [PMID:27878757]
3. Gauvreau GM, FitzGerald JM, Boulet LP, Watson RM, Hui L, Villineuve H, Scime TX, Schlatman AR, Obminski C, Kum J et al..  (2018)  The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma..  Clin Exp Allergy,  48  (4): (445-451).  [PMID:29423947]
4. Grozdanovic M, Laffey KG, Abdelkarim H, Hitchinson B, Harijith A, Moon HG, Park GY, Rousslang LK, Masterson JC, Furuta GT et al..  (2019)  Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness..  J Allergy Clin Immunol,  143  (2): (669-680.e12).  [PMID:29778505]
5. Filippone RT, Robinson AM, Jovanovska V, Stavely R, Apostolopoulos V, Bornstein JC, Nurgali K.  (2018)  Targeting eotaxin-1 and CCR3 receptor alleviates enteric neuropathy and colonic dysfunction in TNBS-induced colitis in guinea pigs..  Neurogastroenterol Motil,  30  (11): (e13391).  [PMID:29968270]
6. Sui Y, Zhang Y, Dong C, Xu B, Sun X.  (2019)  The small molecular CCR3 antagonist YM344031 attenuates neurodegenerative pathologies and improves learning and memory performance in a mouse model of Alzheimer's disease..  Brain Res,  1719  (3): (1-10).  [PMID:31121157]

Solution Calculators